Oncology
ASCO | Jun 4-8, 2021 | Virtual
SOHO | Sep 8-11, 2021 | Houston, TX | Virtual
NCCN (Hem) | Oct 15-16, 2021 | Virtual
SITC | Nov 10-14, 2021 | Washington, DC | Virtual
ASH | Dec 11-14, 2021 | Atlanta, GA | Virtual
Vaccines
APhA | Mar 12-15, 2021 | Virtual
ACP | Apr 29-May 1, 2021 | Virtual
AAFP | Sep 28-Oct 2, 2021 | Virtual
IDWeek | Sep 29-Oct 3, 2021 | San Diego, CA
AAP | Oct 8-12, 2021 | Philadelphia, PA
Respiratory
AAAAI | Feb 26-Mar 1, 2021 | Virtual
ATS | May 14-19, 2021 | Virtual
CHEST | Oct 17-20, 2021 | Orlando, FL | Virtual
AAFP | Sep 28-Oct 2, 2021 | Virtual
ACAAI | Nov 4-8, 2021 | New Orleans, LA
To report suspected adverse reactions, please call us at 1-888-825-5249, or call the FDA at 1-800-FDA-1088 You may also report suspected adverse reactions to the FDA at www.fda.gov/medwatch.
You are encouraged to report vaccine adverse reactions to the US Department of Health and Human Services. Visit www.vaers.hhs.gov to file a report, or call 1-800-822-7967.
First Lastname
Title
First Lastname
Title
First Lastname
Title
First Lastname
Title
First Lastname
Title
First Lastname
Title
December 1-4, 2018
March 16-19, 2019
For a copy of a poster please call 1-877-475-6448
June 11-21, 2020 | Virtual
Dec 10?14, 2019 | San Antonio, Texas
Pilot Neoadjuvant Study of Niraparib in HER2-Negative, BRCA-Mutated Resectable Breast Cancer
September 9-12, 2020 | Virtual Meeting
September 9-12, 2020 | Virtual Meeting
1. Symposium: The Evolving Therapeutic Landscape in Relapsed/Refractory Multiple Myeloma
April 10-15, 2021 and May 17-21, 2021 | Virtual
4. POSTER: Meta-analysis of pazopanib and trabectedin in 2L+ metastatic synovial sarcoma (2L+ mSS)
5. POSTER: Unmet needs in metastatic synovial sarcoma across EU-5 countries
March 19-25, 2021 | Virtual Meeting
April 20, 22, 27, 29, 2021 | Virtual
April 20, 22, 27, 29, 2021 | Virtual Meeting
December 14-16, 2020 | Virtual Meeting
December 14-16, 2020 | Virtual Meeting
4. Systematic Literature Review of Efficacy and Safety of First-Line Maintenance Therapy Trials
Apr 27, 2020 | Virtual Annual Meeting I
Mar 13-16, 2020 | Philadelphia, PA (Cancelled due to COVID-19)
Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pathogenesis, Diagnosis, and Management
The Role of Eosinophilic and Their Potential Heterogeneity in Airways Disease
May 29-June 2, 2020 | Virtual Meeting
May 29-June 2, 2020 | Virtual Meeting
21. PUBLICATION ONLY: Real-World Treatment Patterns of Maintenance therapy in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: Are Some Patients Missing Out?
22. PUBLICATION ONLY: Treatment Patterns of Advanced or Recurrent Endometrial Cancer Following Platinum-Based Therapy in the US Real-World Setting
23. PUBLICATION ONLY: Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab
24. PUBLICATION ONLY: DREAMM-1: Patient Perspectives from the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed and Refractory Multiple Myeloma (RRMM)
25. PUBLICATION ONLY: DREAMM-2: Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed Relapsed/Refractory Multiple Myeloma
26. PUBLICATION ONLY: Current Treatment Efficacy for Metastatic Soft Tissue Sarcoma: A Targeted Literature Review
27. PUBLICATION ONLY: Qualitative Patient Interviews on Symptoms and Impacts in Metastatic Synovial Sarcoma (mSS)
28. PUBLICATION ONLY: Epidemiology of Adenoid Cystic Carcinoma in the United States
May 29-June 2, 2020 | Virtual Meeting
Belantamab mafodotin:
Dostarlimab
ICOS Agonist IgG4 Antibody
TIM-3 Antagonist Antibody (Cobolimab)
LAG-3 Antagonist Antibody (TSR-033)
STING Agonist (GSK3745417)
Bintrafusp Alfa Bifunctional TGF-? ?Trap?/Anti-PD-L1 Fusion Protein
OX40 Agonist Antibody (GSK3174998)
Belantamab Mafodotin - Anti-BCMA Immunoconjugate
NY-ESO-ImmTAC (IMCnyeso)
Anti-CD96 Antibody (GSK6097608)
Molibresib BET Inhibitor
PRMT5 Inhibitor (GSK3326595) and Type I PRMT Inhibitor (GSK3368715)
PI3K? Inhibitor (GSK2636771)
Niraparib (PARP Inhibitor)
October, 2018
June, 2019
June, 2019
1. Chaudhuri R, Caruso C, Chupp G, et al. International Differences in the Use of Mepolizumab to Treat Severe Asthma ? Impact of Reimbursement Policies. [Abstract A1595].
2. Corren J, Molfino N, Silver J, et al. Patterns of ICS Reduction in Patients with Severe Asthma on Mepolizumab. [Abstract A1604].
3. Hahn B, Casale T, Molfino N, et al. Real-World Effectiveness of Mepolizumab in Patients with Respiratory Comorbidities and Severe Asthma. [Abstract A1606].
4. Humbert M, Liu MC, Moore WC, et al. Previous Exacerbations Predict the Risk of Future Exacerbations After Stopping Versus Continuing Mepolizumab Treatment: Secondary Analysis of the COMET Trial. [Abstract A1445].
5. Israel E, Canonica GW, Brusselle G, et al. Systematic Review of Real-World Effectiveness and Safety Studies of Mepolizumab in Treating Severe Eosinophilic Asthma. [Abstract A1358].
6. Nagase H, Tamaoki J, Suzuki T, et al. Real-World Effectiveness of Mepolizumab in Reducing Asthma Exacerbations in Japan. [Abstract A1429].
7. Ramos-Barbn D, Bals R, Crimi N, et al. How Real-World Mepolizumab Users in the REALITI-A Study Relate to the Recruitment Criteria Applied in the Randomized, Placebo-Controlled Trials of Subcutaneous Mepolizumab in Severe Eosinophilic Asthma. [Abstract A1357].
1. Chupp G, Alobid I, Lugogo N, et al. Mepolizumab Reduces Systemic Corticosteroid Use in Patients with Chronic Rhinosinusitis with Nasal Polyps. [Abstract A1344].
1. Akuthota P, Requena G, Van den Bosch J, et al. Description of Hypereosinophilic Syndrome (HES) and Subtypes in North America. [Abstract A1352].
2. Pane F, Lefevre G, Kwon N, et al. Impact of Mepolizumab on Disease Flares in Patients with Hypereosinophilic Syndrome. [Abstract A1809].
3. Steinfeld J, Gleich GJ, Roufosse F, et al. Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study. [Abstract A1352].
1. Busse W, Abbott CB, Chang S, et al. CAPTAIN: Effects of Asthma Onset in Childhood Versus Adulthood on Response to Triple Therapy in Patients with Inadequately Controlled Asthma on Inhaled Corticosteroid/Long-Acting ?2-Agonist. [Abstract A1439].
2. Gardiner F, Pizzichini E, Bailes Z, et al. A Comparison of Clinic Versus Home Spirometry in the CAPTAIN Study. [Abstract A1348].
3. Gardiner F, Pizzichini E, Pavord I, et al. CAPTAIN: Effects of Adding the Long-Acting Muscarinic Antagonist Umeclidinium to Inhaled Corticosteroid/Long-Acting ?2-Agonist Therapy on Symptoms in Patients with Inadequately Controlled Asthma. [Abstract A1349].
4. Roberts M, Meeraus W, Cheng WY, et al. Development of Claims-Based Definitional Algorithms for Moderate and Severe Asthma Exacerbations and Quantification of Exacerbation Rates in Adult Asthmatic Patients Treated with ICS-LABA. [Abstract A1350].
5. Wells JR, Chandler D, Fowler A, et al. Patient Experience of Moderate Exacerbations in Asthma: Results of Concept Elicitation Interviews. [Abstract A4132].
1. Bogart M, Germain G, Huang SP, et al. Benefit of Prompt Versus Delayed Initiation of Single Inhaler Triple Therapy on Exacerbations and Healthcare Costs Among Patients with Chronic Obstructive Pulmonary Disease in the US. [Abstract A2252].
2. Bogart M, Oakland T, Liu Y, et al. Triple Therapy Treatment Pathways in Chronic Obstructive Pulmonary Disease (COPD): A Real-World Predictive Model. [Abstract A2313].
3. Espinosa J, Soares C, Abreu G, et al. Controller Therapy Evaluation Among COPD Patients from Hospital Italiano, Argentina. [Abstract A1630].
4. Espinosa J, Nogueira T, Soares C, et al. Characteristics of COPD Patients Before First Controller Therapy from Hospital Italiano, Argentina. [Abstract A3136].
5. Ferrera MC, Lopez CL, et al. Routinely Collected Clinical Features Are Associated with COPD Exacerbations in Individuals Without an Exacerbation History: A COPDGene Analysis. [Abstract A2293].
6. Jones PW, Shukla S, Tombs L, et al. Uncovering the Relationship Between the COPD Assessment Test and St George?s Respiratory Questionnaire in Patients with Chronic Obstructive Pulmonary Disease: A Post-Hoc Analysis of the IMPACT, FULFIL, and EMAX trials. [Abstract A4565].
7. Mammen MJ, Carr TF, Criner GJ, et al. All-Cause Mortality by Subgroup in Patients with Chronic Obstructive Pulmonary Disease: Post Hoc Analysis of the IMPACT Trial. [Abstract A2241].
8. Mammen MJ, Carr TF, Criner GJ, et al. Risk of All-Cause Mortality During and After Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease (COPD): Post Hoc Analysis of the IMPACT Trial. [Abstract A2243].
9. Mapel D, Bogart M, Criner GJ, et al. Reduction in Emergency Department (ED) Visits in Patients with Chronic Obstructive Pulmonary Disease (COPD): Analysis of the IMPACT Trial. [Abstract A2242].
10. Osterland A, Yasuda M, Huang S, et al. Real World Peak Inspiratory Flow Rate Assessment by the In-Check DIAL (set to Ellipta Resistance) Demonstrates All Asthma and COPD Patients Achieved ? 30 L/min. [Abstract A2163].
11. Wells JM, Bhatt SP, Carr TF, et al. An Analysis of the IMPACT Trial Assessing Single-Inhaler Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI and UMEC/VI Using a Composite Adverse Event Outcome in Patients With COPD. [Abstract A2240].
1.Chapman KR, An L, Bosnic-Anticevich S, et al. Asthma Patients? and Physicians? Perspectives on the Burden and Management of Asthma (APPaRENT). [Abstract A1453]
1.Jones P, Ma Q, Yang Y, et al. Development of a COPD Exacerbation Recognition Tool (CERT) for Use by Chinese Patients: Item Reduction and Final Content. [Abstract A1668]
1.Averell CM, Lalibert F, Germain G, et al. Real-World Impact of Adherence to ICS/LABAs on Asthma Outcomes in the US. [Abstract A1605]
1. Chaudhuri R, Canonica GW, Bals R, et al. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. [Poster No. 714; Abstract A4267].
2. Hahn B, Bogart M, Silver J, et al. Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. [Poster No. 804; Abstract A7741].
3. Molfino NA, Averell CM, Hahn BA, et al. Patients with Uncontrolled Asthma Eligible for a Biologic. [Poster No. 801; Abstract A7738].
4. Moore WC, Kornmann O, Humbert M, et al. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. [Oral presentation available here; Abstract A4211].
5. Moraes F, Abreu G, Nogueira T, et al. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. [Poster No. 712; Abstract A1827].
6. Moraes F, Abreu G, Nogueira T, et al. Prevalence of asthma and severe asthma in patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. [Poster No. 710; Abstract A1825].
7. Verhamme K, de Ridder M, Webb D, et al. Differences in Patient Characteristics between Asthma Patients with and without Eosinophil Measurements. [Poster No. P792; Abstract A5630].
8. Wu AC, McMahon PM, Mendelsohn A, et al. Use of Mepolizumab among Individuals with Asthma in the U.S. [Poster No. P742; Abstract A4771].
1. Prazma C, Bernstein D, Brightling C, et al. The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. [Poster No. 1301; Abstract A1312].
1. Bell CF, Blauer-Peterson C. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. [Poster No. P1286; Abstract A6579].
1. Steinfeld J, Roufosse F, Kahn JE, et al. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. [Oral presentation available here; Abstract A4212].
1. Averell CM, Hahn BA, Zografos L, et al. Assessment of Asthma Control in Respiratory Specialist Offices in the US. [Poster No. P711; Abstract A1826].
2. Bogart M, Chastek B, White J, et al. Treatment Patterns and Disease Burden of Triple Therapy in Asthma. [Poster No. P805; Abstract A7742].
3. Davitte J, DeBarmore B, Hinds D, et al. Asthma control among the treated U.S. asthma population in Practice Fusion?s Electronic Medical Record Research Database, 2015-2018. [Poster No. P699; Abstract A1814].
4. Fowler A, Kerstjens HAM, Bailes Z, et al. CAPTAIN Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship With Trough FEV1. [Poster No. P788; Abstract A5626].
5. Kerstjens HA, Pavord ID, Peachey G, et al. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. [Oral presentation available here; Abstract A4209].
6. Lee LA, Boulet LP, Fowler A, et al. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. [Poster No. P787; Abstract A5625].
7. Molfino NA, Averell CM, Hahn BA, et al. Real World Evidence in Asthma: Pulmonary Function and Asthma Control in Respiratory Specialty Clinics in the US. [Poster No. P372; Abstract A6482]
8. Pavord ID, Fowler A, Kerstjens HA, et al. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. [Oral presentation available here; Abstract A6247].
9. Sansbury LB, Hinds D, Chao J, et al. Treatment sequencing among asthma patients who were newly treated with long-acting antimuscarinic antagonist (LAMA) in the United States. [Poster No. P713; Abstract A1828]
10. Tabberer M, von Maltzahn R, Bacci E, et al. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS: Asthma in Two Clinical Trials of Moderate to Severe Asthma. [Poster No. P786; Abstract A5624]
1. Anderson M, Drummond MB, Jain R, et al. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. [Poster No. P813; Abstract A4302].
2. Ferguson GT, Brown N, Compton C, et al. Once-Daily Single-Inhaler Versus Twice-Daily Multiple-Inhaler Triple Therapy: Two Replicate Trials in Patients With Chronic Obstructive Pulmonary Disease (COPD). [Poster No. P806; Abstract A4295].
3. Halpin DMG, Worsley S, Ismaila AS, et al. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. [Poster No. P824; Abstract A4313].
4. Mularski R, Wu B, Fuoco MJ, et al. Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations. [Poster No. P276; Abstract A4811].
5. Mularski RA, Drummond MB, Jain R, et al. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. [Poster No. P1045; Abstract A5050].
6. Obeid D, Bansal S, Brown N, et al. Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations. [Poster No. 805; Abstract A4294].
7. Bjermer L, Maltais F, Vogelmeier CF, et al. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. [Poster No. P1091; Abstract A3326].
8. Cole AL, Moretz C, Mu G, et al. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database. [Poster No. 817; Abstract A4306].
9. Kerwin EM, Maltais F, Boucot IH, et al. Analysis of a Composite Endpoint of Exacerbation and Early Study Treatment Withdrawal in Symptomatic Patients With COPD Free of Inhaled Corticosteroids: A Post Hoc Analysis of the EMAX Trial. [Poster No. 518; Abstract A4579].
10. Kerwin EM, Bjermer L, Maltais F, et al. Rescue Medication Use as an Indicator of Symptom Burden in Patients With COPD: A Post Hoc Analysis of the EMAX Trial. [Poster No. 1089; Abstract A3324].
11. Moretz C, Hahn B, White J, et al. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. [Poster No. 811; Abstract A4300].
12. Vogelmeier CF, Kerwin EM, Naya IP, et al. Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. [Poster No. 1053; Abstract A5058].
13. Vogelmeier CF, Boucot IH, Kerwin EM, et al. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. [Poster No. 1090; Abstract A3325].
14. Keir HR, Richardson H, Mayhew D, et al. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. [Poster No. P474; Abstract A3997].
1. Exacerbation Reduction in Patients Based Upon Baseline Eosinophil Counts and FEV1 Reversibility
4. Practical Use of ELLIPTA, a Once-Daily, Dry Powder Inhaler for Children With Asthma
5. Nasal Polyp Symptoms: How Well Do Physicians Know Their Patients?
8. Efficacy of Mepolizumab Stratified by Baseline Blood Eosinophil Count
1. Liu M, Taill C, Lee J, et al. Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials. [Abstract/Poster No. P174].
2. Molfino N, Casale T, Silver J, et al. Managing Patients with Severe Asthma and Common Comorbidities of Atopy, Obesity & Depression/Anxiety: Real-world Effectiveness of Mepolizumab. [Abstract/Poster No. P173].
1. Akuthota P, Requena G, van den Bosch J, et al. Description of Hypereosinophilic Syndrome (HES) and Subtypes. [Abstract/Poster No. P448].
2. Rothenberg M, Roufosse F, Faguer S, et al. Impact of Baseline Blood Eosinophil Count on Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome. [Abstract/Poster No. P444].
3. Roufosse F, Butterfield J, von Maltzahn R, et al. Impact of Mepolizumab on Symptom Severity in Patients with Hypereosinophilic Syndrome. [Abstract/Poster No. P446].
1. Lee S, Tabberer M, Trigg A, et al. Mepolizumab Improves Health Related Quality of Life for Patients with Chronic Rhinosinusitis with Nasal Polyps: Data from the SYNAPSE study. [Abstract/Poster No. P399].
2. Tabberer M, Trigg A, Busse W, et al. Mepolizumab reduces disease symptoms for Patients with Chronic Rhinosinusitis with Nasal Polyps: Data from the SYNAPSE study. [Abstract/Poster No. P402].
1. Hanania N, Bailes Z, Chang S, et al. CAPTAIN: Effects of Cardiovascular Risk on Response to Triple Therapy in Patients With Inadequately Controlled Asthma on Inhaled Corticosteroids/Long-acting ?2-agonists (ICS/LABA). [Abstract/Poster No. P179].
2. Maselli D, Chang S, Fowler A, et al. CAPTAIN: Effects of body mass index (BMI) on response to triple therapy in patients with inadequately controlled asthma on ICS/LABA. [Abstract/Poster No. P176].
1. Chapman KR, Devouassoux G, Liu MC, et al. Switch from omalizumab to mepolizumab in severe eosinophilic asthma: effect of weight and BMI. [Poster No. P205; Abstract 8039].
2. Liu M, Bel E, Kornmann O, et al. Clinician/Patient Perception: Asthma Severity Decreases and Response Increases With Continuing Versus Stopping Long-term Mepolizumab (COMET). [Poster No. P211; Abstract 8056].
1. Averell CM, Germain G , Lalibert F, et al. HO-19-19563 - Asthma-Related Exacerbations and SABA Use Associated With Once-Daily Fluticasone Furoate/Vilanterol Compared To Twice-Daily Budesonide/Formoterol. [Poster No. P218; Abstract 8091].
2. Averell CM, Lalibert F, Germain G, et al. HO-18-18648 - Disease Burden And Treatment Adherence Among Children And Adolescent Patients With Asthma. [Poster No. P217; Abstract 8079].
3. Hanania N, Bailes Z, Barnes N, et al. CAPTAIN Study: Effects of Fluticasone Furoate/Umeclidinium/Vilanterol on FEV1 Improvement in Asthma According to Age. [Poster No. P206; Abstract 8041].
4. Oppenheimer J, Brusselle G, Busse W, et al. CAPTAIN Study: Treatment Outcomes from Fluticasone Furoate/Umeclidinium/Vilanterol According to History of Severe Asthma Exacerbations. [Poster No. P202; Abstract 8031].
1. Irani A-M, Prazma C, Bajaj B, et al. Successful Liver Transplantation in a Patient with Hypereosinophilic Syndrome treated with Mepolizumab. [Poster No. M239; Abstract 9050].
1. Bachert C, Sousa A, Han J, et al. Mepolizumab for Chronic Rhinosinusitis With Nasal Polyps: Comorbid Asthma, NSAID Exacerbated Respiratory Disease, Eosinophil Stratification. [Poster No. P503; Abstract 8052].
1. Silver J, Bogart M, Molfino N, et al. Reasons why patients with severe asthma discontinue biologic treatment. Poster No. P0018.
2. Silver J, Bogart M, Molfino N, et al. Impact of mepolizumab in patients with life-threatening asthma. Poster No. P0017.
1. Nathan R, Boulet L-P, Kerstjens HA, et al. CAPTAIN Study: Effect of baseline lung function on response to triple therapy in patients with asthma inadequately controlled on inhaled corticosteroid/long-acting ?2-agonist therapy. Poster No. P1483.
2. Ramesh N, Hegewald M, Maselli DJ, et al. Views of US pulmonologists on the prevalence of uncontrolled asthma, treatment decisions and the role of treatable traits: results from the CHEST Pulse Surveys. Poster No. P1488.
3. Sule N, Fowler A, Kerstjens HA, et al. CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial. Oral presentation.
4. Zhang S, White J, Meeraus W, et al. Prevalence of asthma control and the associated disease burden in US patients with asthma treated with a fixed-dose combination of inhaled corticosteroid and long-acting ?2-agonist. Poster No. P1512.
1. Anzueto A, Obeid D, Bansal S, et al. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol compared with tiotropium monotherapy in chronic obstructive pulmonary disease: a post hoc analysis by airflow limitation. Poster No. P1440.
2. Bogart M, Wu B, Germain G, et al. Real-world adherence to single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in a commercially insured US population. Poster No. P1444.
3. Calverley PMA, Celli BR, Crim C, et al. Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate-containing therapy: Post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation. Poster No. P1448.
4. Criner GJ, Barnes N, Brusselle G, et al. Demographic and clinical characteristics of patients experiencing on-treatment exacerbations, on-treatment death or premature study treatment withdrawal: The IMPACT Trial. Poster No. P1454.
5. Dransfield MT, Halpin DMG, Han MK, et al. Time-dependent risk of cardiovascular events following an exacerbation in patients with COPD: post hoc analysis from the IMPACT trial. Poster No. P1458.
6. Han MK, Bratton DJ, Hartley B, et al. Benefit?risk profiles of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease: a Markov model. Oral presentation.
7. Hosking L, Yeo A, Hoffman J, et al. Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and its components. Poster No. P1501.
8. Mannino D, Siddall J, Small M, et al. Cross-sectional survey to assess chronic obstructive pulmonary disease (COPD) medication use by United States (US) physicians. Poster No. P1446.
9. Soler X, Siddall J, Small M, et al. Cross-sectional survey to assess the burden of nocturnal symptoms in patients with chronic obstructive pulmonary disease (COPD). Poster No. P1445.
10. Slade D, Ray R, Moretz C, et al. Medication adherence and COPD-related costs among patients with COPD treated with umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO). Poster No. 1467.
11. Slade D, Ray R, Moretz C, et al. Umeclidinium/vilanterol (UMEC/VI) compared with tiotropium (TIO) for time-to-first inpatient admission among patients with chronic obstructive pulmonary disease in a managed care population. Poster No. 1465.
12. Slade D, Ray R, Moretz C, et al. Impact of umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), fluticasone propionate/salmeterol (FP/SAL), and budesonide/formoterol (B/F) on time-to-first severe exacerbation among patients with chronic obstructive pulmonary disease with high comorbidities and high costs. Poster No. 1466.
13. McCreary G, Yawn BP, Linnell J, et al. Assessment of patient interaction with a dry powder inhaler electronic medication monitor and integrated system within the Chronic Obstructive Pulmonary Disease Foundation Patient Powered Research Network. Poster No. P1481.
14. Thompson-Leduc P, Ghaswalla P, Cheng WY, et al. Chronic obstructive pulmonary disease is associated with an increased risk of herpes zoster: a retrospective analysis of a United States claims database from 2013-2018. Poster No. P1505.
Mar 13-16, 2020
Mar 13-16, 2020
1. Exacerbation Reduction in Patients Based Upon Baseline Eosinophil Counts and FEV1 Reversibility
4. Practical Use of ELLIPTA, a Once-Daily, Dry Powder Inhaler for Children With Asthma
5. Nasal Polyp Symptoms: How Well Do Physicians Know Their Patients?
8. Efficacy of Mepolizumab Stratified by Baseline Blood Eosinophil Count
Oct 21-25, 2020
1. #Vaccine Twitter Influencers: Is it Just About Reach and Followers?
5. Assessment of Recombinant Zoster Vaccine Second-Dose Completion in the United States
6. Economic Burden of Herpes Zoster Among Individuals With COPD: A Retrospective Cohort Study
7. The Potential for Reducing Opioid and Analgesic Prescriptions via Herpes Zoster Vaccination
Apr 27, 2020 | Virtual Annual Meeting I
December 5-8, 2020 | Virtual Meeting
10. Population-level Projections for Multiple Myeloma Patients by Line of Therapy in the USA
Publication Only: Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data From the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)
Publication Only: Real-world Incidence and Clinical and Economic Burden of Managing Ocular Events (OE) in Patients with Active Multiple Myeloma (MM)
November 9-14, 2020 | Virtual Meeting
September 19-21, 2020 | Virtual Meeting
September 19-21, 2020 | Virtual Meeting
November 16-19, 2020 | Virtual Meeting
NY-ESO-1 TCR T Cell (GSK3377794)
February 27-29, 2020 | Scottsdale, AZ
October 3-4, 2020 | Virtual Meeting
January 23-25, 2020 | San Francisco, CA
October 22-25, 2020 | Virtual
2. Burden of Illness of Lupus Nephritis in Patients With Systemic Lupus Erythematosus
November 5-9, 2020 | Virtual
From June 3, 2020 | Virtual
October 22-25, 2020 | Virtual
May 18-20, 2020 | Virtual Meeting
September 19-21, 2020 | Virtual Meeting
1. Treatment Options for Women with Advanced Ovarian Cancer: Evaluating the Evidence
Feb 26?Mar 1, 2021